Hopforhep is a breakthrough new medication for the treatment of patients with chronic hepatitis C.
Sofosbuvir is a direct-acting antiviral agent and interferes with the HCV lifecycle, restraining the viral replication, allows most patients to be treated successfully without the use of peginterferon an injectable drug with severe side effects.


Indications and usage:it is a hepatitis c virus (hcv) nucleotide analog ns5b polymerase inhibitor indicated for the treatment of chronic hepatitis c (chc) infection as a component of a combination antiviral treatment regimen.*efficacy has been established in subjects with hcv genotype 1, 2, 3 or 4 infection, including those with hepatocellular carcinoma meeting milan criteria (awaiting liver transplantation) and those with hcv/hiv-1 co-infection.*dosage and administration:* one 400 mg tablet taken once daily with or without food.* should be used in combination with ribavirin or in combination with pegylated interferon and ribavirin for the treatment of chc.recommended combination therapy:hcv mono-infected and hcv/hiv-1 co-infected treatment durationgenotype 1 or 4 sovaldi + peg-interferon alfa + ribavirin 12 weeksgenotype 2 so